CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.75
+0.03 (0.11%)
as of Sep 14, 2026, 5:42:20 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
TOP PICK

Pfizer Inc(PFE)

Apr 22, 2002
(Was a top pick on Mar 23 no change) A fan of pharmaceuticals and thinks this is the best. Goor R&D and sales.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$37.11

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 17, 2002
Great com;pany. Valuation is too high.
Photo of Ian NakamotoIan NakamotoUnlock Rating
$37.85

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
STRONG BUY

Pfizer Inc(PFE)

Apr 15, 2002
Great product line/sales force. Good price.
Photo of Neil MurdockNeil MurdockUnlock Rating
$39.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 10, 2002
Has a good pipeline. Should improve towards the end of the year.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$39.34

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Apr 02, 2002
Great pipeline of products, but has trouble breaking through the $44 level.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 28, 2002
Very expensive now. 8/10 X Book. Has some potential, but caution.
Photo of Ross HealyRoss HealyUnlock Rating
$39.74

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 15, 2002
Trading at high multiples.
Photo of Jonathen Wellum, B. Comm, B. ScJonathen Wellum, B. Comm, B. ScUnlock Rating
$41.37

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Mar 12, 2002
A great long term hold for growth. Strong pipeline.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$39.85

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Mar 08, 2002
Prefers Glaxco Smith Klein.
Photo of David DriscollDavid DriscollUnlock Rating
$40.01

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 22, 2002
Prefers this and J&J over Merk. Will eventually give a 15/20% return.
Photo of Brad WillockBrad WillockUnlock Rating
$40.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 17, 2002
At a good price. Have a good drug pipeline. A premium company. Earnings growth should be 20% plus.
Photo of Glenn Paradis, BA, CFAGlenn Paradis, BA, CFAUnlock Rating
$40.13

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
(Was a top pick on June 14 down 5%) Has the best patent protection folio. Should grow 25% in 2002 and 15% for the next two years.
Photo of Noah Blackstein, B.A., CFANoah Blackstein, B.A., CFAUnlock Rating
$40.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 11, 2002
They have a good product line plus good new product development is excellent. Very cheap now.
Photo of Steven WipperstegSteven WipperstegUnlock Rating
$40.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 08, 2002
Good pipeline. Likes the price.
Photo of Jeff MorrisonJeff MorrisonUnlock Rating
$39.59

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2002
Likes the pharmaceutical sector. Has a good pipeline for its drugs.
Photo of Neil MurdockNeil MurdockUnlock Rating
$39.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 826 to 840 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DML.TO -0.18$4.01
BIR.TO 0.06$6.38
M 1.025$23.105
ZRE.TO 0.09$22.46
HMAX.TO -0.02$17.51
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79
URI 8.38$997.5
BBD.B.TO 8.2$309.02

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like